Angus C.  Russell net worth and biography

Angus Russell Biography and Net Worth

Mr. Russell has been chairman of the board since May 2018, and a director since August 2014. He is also a member of Mallinckrodt’s Science and Technology Committee and its Audit Committee.

He has served as the non-executive chairman of Revance Therapeutics, Inc. since March 2014. Mr. Russell has also served as a director of Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.) since December 2014 and as a director of TherapeuticsMD, Inc. since March 2015.

Mr. Russell served as a director of Questcor Pharmaceuticals, Inc. from June 2013 until Questcor was acquired by Mallinckrodt in August 2014. He served as chief executive officer of Shire Plc from 2008 until his retirement in April 2013 and was a member of its board of directors from 1999 to 2013. From 1999 to 2008, Mr. Russell served as chief financial officer of Shire. Prior to joining Shire, he served at ICI, Zeneca and AstraZeneca, most recently as vice president of corporate finance at AstraZeneca. He was a director of InterMune, Inc. from 2011 to 2014.

Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K.

What is Angus C. Russell's net worth?

The estimated net worth of Angus C. Russell is at least $261,800.00 as of August 23rd, 2019. Mr. Russell owns 93,500 shares of Revance Therapeutics stock worth more than $261,800 as of June 19th. This net worth approximation does not reflect any other assets that Mr. Russell may own. Learn More about Angus C. Russell's net worth.

How do I contact Angus C. Russell?

The corporate mailing address for Mr. Russell and other Revance Therapeutics executives is 7555 GATEWAY BLVD., NEWARK CA, 94560. Revance Therapeutics can also be reached via phone at (615) 724-7755 and via email at [email protected]. Learn More on Angus C. Russell's contact information.

Has Angus C. Russell been buying or selling shares of Revance Therapeutics?

Angus C. Russell has not been actively trading shares of Revance Therapeutics within the last three months. Most recently, on Monday, December 13th, Angus C. Russell bought 6,400 shares of Revance Therapeutics stock. The stock was acquired at an average cost of $15.74 per share, with a total value of $100,736.00. Learn More on Angus C. Russell's trading history.

Who are Revance Therapeutics' active insiders?

Revance Therapeutics' insider roster includes Mark Foley (CEO), Dwight Moxie (SVP), Aubrey Rankin (Insider), Angus Russell (Director), and Tobin Schilke (CFO & Principal Accounting Officer ). Learn More on Revance Therapeutics' active insiders.

Are insiders buying or selling shares of Revance Therapeutics?

In the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 107,201 shares worth more than $1,859,572.74. The most recent insider tranaction occured on April, 16th when insider Erica Jordan sold 2,392 shares worth more than $9,089.60. Insiders at Revance Therapeutics own 3.5% of the company. Learn More about insider trades at Revance Therapeutics.

Information on this page was last updated on 4/16/2024.

Angus C. Russell Insider Trading History at Revance Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2021Buy6,400$15.74$100,736.00View SEC Filing Icon  
See Full Table

Angus C. Russell Buying and Selling Activity at Revance Therapeutics

This chart shows Angus C Russell's buying and selling at Revance Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Revance Therapeutics Company Overview

Revance Therapeutics logo
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $2.80
Low: $2.74
High: $2.90

50 Day Range

MA: $3.36
Low: $2.67
High: $4.44

2 Week Range

Now: $2.80
Low: $2.57
High: $29.43


1,428,356 shs

Average Volume

1,605,170 shs

Market Capitalization

$292.46 million

P/E Ratio


Dividend Yield